EUVIMEDEUVIMED entdecken
Open Access

The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic

Ida-Lina Diak, Kimberley Swank, Kate McCartan, Maya Beganovic, James Kidd, Neha Gada, Rachna Kapoor, Lisa Wolf, Laura Kangas, Jo Wyeth, Toni Salvatore, Melina Fanari und 4 weitere

Drug Safety · 2023-02 · 46 (2) · 145-155

DOI: 10.1007/s40264-022-01256-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Safety, online erschienen am 02.12.2022. Verfasst von Ida-Lina Diak und 15 weiteren Autor:innen. Beteiligte Einrichtung: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Ida-Lina.D…. Hauptthemen laut MEDLINE: COVID-19, Poisons. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: On 4 February, 2020, the Secretary of the Department of Health and Human Services declared a public health emergency related to coronavirus disease 2019 (COVID-19), and on 27 March, 2020 declared circumstances existed to justify the authorization of the emergency use of drug and biological products (hereafter, "drugs") for COVID-19. At the outset of the pandemic with uncertainty relating to the virus, many drugs were being used to treat or prevent COVID-19, resulting in the US Food and Drug Administration's (FDA's) need to initiate heightened surveillance across these drugs. OBJECTIVE: We aimed to describe the FDA's approach to monitoring the safety of drugs to treat or prevent COVID-19 across multiple data sources and the subsequent actions taken by the FDA to protect public health. METHODS: The FDA conducted surveillance of adverse event and medication error data using the FDA Adverse Event Reporting System, biomedical literature, FDA-American College of Medical Toxicology COVID-19 Toxicology Investigators Consortium Pharmacovigilance Project Sub-registry, and the American Association of Poison Control Centers National Poison Data System. RESULTS: From 4 February, 2020, through 31 January, 2022, we identified 22,944 unique adverse event cases worldwide and 1052 unique medication error cases domestically with drugs to treat or prevent COVID-19. These were from the FDA Adverse Event Reporting System (22,219), biomedical literature (1107), FDA-American College of Medical Toxicology COVID-19 Toxicology Investigator's Consortium Sub-registry (638), and the National Poison Data System (32), resulting in the detection of several important safety issues. CONCLUSIONS: Safety surveillance using near real-time data was critical during the COVID-19 pandemic because the FDA monitored an unprecedented number of drugs to treat or prevent COVID-19. Additionally, the pandemic prompted the FDA to accelerate innovation, forging new collaborations and leveraging data sources to conduct safety surveillance to respond to the pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19PoisonsHumansUnited StatesPharmaceutical PreparationsPandemicsUnited States Food and Drug AdministrationPharmacovigilance

Substanzen

Pharmaceutical PreparationsPoisons

Autor:innen und Institutionen

  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Ida-Lina.Diak@fda.hhs.gov.
  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Zitieren

APA

Diak, I. L., Swank, K., McCartan, K., Beganovic, M., Kidd, J., Gada, N., Kapoor, R., Wolf, L., Kangas, L., Wyeth, J., Salvatore, T., Fanari, M., LeBoeuf, A. A., Mishra, P., Blum, M. D., & Dal Pan, G. (2023). The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic. Drug Safety, 46(2), 145-155. https://doi.org/10.1007/s40264-022-01256-2

Vancouver

Diak IL, Swank K, McCartan K, Beganovic M, Kidd J, Gada N, et al. The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic. Drug Safety. 2023;46(2):145-155. doi:10.1007/s40264-022-01256-2

BibTeX
@article{Diak2023,
  author = {Diak, Ida-Lina and Swank, Kimberley and McCartan, Kate and Beganovic, Maya and Kidd, James and Gada, Neha and Kapoor, Rachna and Wolf, Lisa and Kangas, Laura and Wyeth, Jo and Salvatore, Toni and Fanari, Melina and LeBoeuf, Andrew A and Mishra, Poonam and Blum, Michael D and Dal Pan, Gerald},
  title = {The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic},
  journal = {Drug Safety},
  year = {2023},
  volume = {46},
  number = {2},
  pages = {145--155},
  doi = {10.1007/s40264-022-01256-2}
}
Kostenlos starten →